The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study
- 30 June 1992
- journal article
- clinical trial
- Published by Elsevier in International Journal of Cardiology
- Vol. 35 (3) , 387-395
- https://doi.org/10.1016/0167-5273(92)90238-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- ATRIAL NATRIURETIC PEPTIDE: An Important Factor in Sodium and Blood Pressure RegulationThe Lancet, 1989
- Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension.Hypertension, 1987
- Effect of β1‐adrenoceptor blockade on plasma levels of atrial natriuretic peptide during exercise in normal manClinical Physiology and Functional Imaging, 1987
- Subacute Hemodynamic Effects of Nebivolol in Man at Rest and During ExerciseAngiology, 1987
- Haemodynamic effects in man during exercise of a single oral dose of narbivolol (R 67555), a new beta‐1‐adrenoceptor blocking agent: A comparative study with atenolol, pindolol, and propranololDrug Development Research, 1986
- Response to placebo treatment in hypertension.Hypertension, 1983
- Effects of 10 Different β-Adrenoceptor Antagonists on Hemodynamics, Plasma Renin Activity, and Plasma Norepinephrine in HypertensionJournal of Cardiovascular Pharmacology, 1983
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978
- Antihypertensive beta blocking action as related to renin and age: A pharmacologic tool to identify pathogenetic mechanisms in essential hypertensionThe American Journal of Cardiology, 1975
- Left Ventricular Volumes and Ejection Fraction by EchocardiographyCirculation, 1971